Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tum...

Por Murakami, Haruyasu, Doi, Toshihiko, Yamamoto, Nobuyuki, Watanabe, Junichiro, Boku, Narikazu, Fuse, Nozomu, Yoshino, Takayuki, Ohtsu, Atsushi, Otani, Satoru, Shibayama, Kazuhiro, Takubo, Takatoshi, Loh, Elwyn
Publicado em 2012

A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma

Por Wen, Patrick Y., Schiff, David, Cloughesy, Timothy F., Raizer, Jeffrey J., Laterra, John, Smitt, Melanie, Wolf, Michael, Oliner, Kelly S., Anderson, Abraham, Zhu, Min, Loh, Elwyn, Reardon, David A.
Publicado em 2011

Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer

Por Cutsem, Eric Van, Eng, Cathy, Nowara, Elzbieta, Świeboda-Sadlej, Anna, Tebbutt, Niall C., Mitchell, Edith, Davidenko, Irina, Stephenson, Joe, Elez, Elena, Prenen, Hans, Deng, Hongjie, Tang, Rui, McCaffery, Ian, Oliner, Kelly S., Chen, Lisa, Gansert, Jennifer, Loh, Elwyn, Smethurst, Dominic, Tabernero, Josep
Publicado no Clin Cancer Res (2014)